Ghrelin for Neuroprotection in Post-Cardiac Arrest Coma: A Randomized Clinical Trial

What Was Tested

Researchers studied Ghrelin in this randomized controlled trial publication.

Who Took Part

The abstract describes 20 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

A phase 2, double-blind, placebo-controlled, multicenter, randomized clinical trial, Ghrelin Treatment of Comatose Patients After Cardiac Arrest: A Clinical Trial to Promote Cerebral Recovery (GRECO), was conducted between January 18, 2019, and October 17, 2022.

Adult patients 18 years or older who were in a comatose state after cardiac arrest were assessed for eligibility; patients were from 3 intensive care units in the Netherlands.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Ghrelin and who got the comparison, which limits bias.

As a double-blind Ghrelin study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Ghrelin, giving a reference point.

Running at several centres spread the Ghrelin study over different clinics and patient groups.

What Was Measured

The subject headings attached to it are Ghrelin, Coma, Neuroprotective Agents, Neuroprotection, Heart Arrest and Out-of-Hospital Cardiac Arrest.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Ghrelin in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 12 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (JAMA neurology), a journal based in United States.

More context: the Ghrelin compound page, all human trials.